| An integrated view of cyclin E function and regulation KT Siu, MR Rosner, AC Minella Cell cycle 11 (1), 57-64, 2012 | 197 | 2012 |
| Targeting cyclin-dependent kinases and cell cycle progression in human cancers L Santo, KT Siu, N Raje Seminars in oncology 42 (6), 788-800, 2015 | 162 | 2015 |
| Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma KT Siu, J Ramachandran, AJ Yee, H Eda, L Santo, C Panaroni, JA Mertz, ... Leukemia 31 (8), 1760-1769, 2017 | 75 | 2017 |
| Multiple myeloma cells induce lipolysis in adipocytes and uptake fatty acids through fatty acid transporter proteins C Panaroni, K Fulzele, T Mori, KT Siu, C Onyewadume, A Maebius, ... Blood, 2021 | 54 | 2021 |
| Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism Y Xu, KL Swartz, KT Siu, M Bhattacharyya, AC Minella Oncogene 33 (24), 3161-3171, 2014 | 34 | 2014 |
| Chromosome instability underlies hematopoietic stem cell dysfunction and lymphoid neoplasia associated with impaired Fbw7-mediated cyclin E regulation KT Siu, Y Xu, KL Swartz, M Bhattacharyya, S Gurbuxani, Y Hua, ... Molecular and cellular biology 34 (17), 3244-3258, 2014 | 31 | 2014 |
| Pim2 is important for regulating DNA damage response in multiple myeloma cells J Ramachandran, L Santo, KT Siu, C Panaroni, N Raje Blood cancer journal 6 (8), e462-e462, 2016 | 29 | 2016 |
| BCL2 blockade overcomes MCL1 resistance in multiple myeloma KT Siu, C Huang, C Panaroni, K Mukaihara, K Fulzele, R Soucy, ... Leukemia 33 (8), 2098-2102, 2019 | 28 | 2019 |
| Effect of the BET inhibitor, Cpi-0610, alone and in combination with lenalidomide in multiple myeloma KT Siu, H Eda, L Santo, J Ramachandran, M Koulnis, J Mertz, RJ Sims, ... Blood 126 (23), 4255, 2015 | 21 | 2015 |
| Arachidonic acid induces ferroptosis-mediated cell-death in multiple myeloma C Panaroni, K Fulzele, R Soucy, KT Siu, K Mukaihara, C Huang, ... Blood 132, 4498, 2018 | 8 | 2018 |
| Low NCOR2 levels in multiple myeloma patients drive multidrug resistance via MYC upregulation T Mori, R Verma, R Nakamoto-Matsubara, KT Siu, C Panaroni, KS Fulzele, ... Blood Cancer Journal 11 (12), 194, 2021 | 7 | 2021 |
| Mature osteoblasts provide a protective niche against multiple myeloma growth and survival within the tumor microenvironment K Fulzele, C Panaroni, R Soucy, KT Siu, K Mukaihara, N Raje Blood 132, 4476, 2018 | 3 | 2018 |
| Osteoclast-Induced Immunosuppression Occurs through Dysregulation of Immune Checkpoint Axes in Multiple Myeloma K Mukaihara, M D'Agostino, C Panaroni, K Fulzele, T Mori, KT Siu, ... Blood 134, 4382, 2019 | 2 | 2019 |
| The pleiotropic immunosuppressive role of osteoclasts in multiple myeloma K Mukaihara, KT Siu, C Panaroni, K Fulzele, R Soucy, C Huang, ... Blood 132, 4447, 2018 | 2 | 2018 |
| Concomitant suppression of IKZF1, IRF4 and Myc contribute to the anti-tumor activity of the BET inhibitor, Cpi-0610, in disease models of multiple myeloma KT Siu, J Ramachandran, AJ Yee, H Eda, L Santo, EK O'Donnell, ... Blood 128 (22), 3320, 2016 | 1 | 2016 |
| Effect of the Wnt-Signaling Inhibitor Sclerostin and Bone Marrow Adipocytes on Multiple Myeloma C Panaroni, KT Siu, KS Fulzele, J Ramachandran, N Raje Blood 128 (22), 2077, 2016 | 1 | 2016 |
| Developing a systems-based understanding of hematopoietic stem cell cycle control KT Siu, AC Minella A Systems Biology Approach to Blood, 189-200, 2014 | 1 | 2014 |
| Overcoming MCL1 Resistance in Multiple Myeloma KT Siu, C Huang, C Panaroni, K Mukaihara, K Fulzele, R Soucy, J Cidado, ... Blood 132, 472, 2018 | | 2018 |
| Role of Sclerostin in Multiple Myeloma Progression C Panaroni, K Fulzele, KT Siu, P Wang, N Raje Blood 130, 4341, 2017 | | 2017 |
| The Biologic Relevance of PIM Kinases in the Context of Multiple Myeloma and Their Potential As Therapeutic Targets in Combination Drug Therapy J Ramachandran, L Santo, H Eda, D Chauhan, KT Siu, M Koulnis, ... Blood 126 (23), 2992, 2015 | | 2015 |
